Therapy for HIV Patients Failing Previous Therapy

In clinical studies of treatment-naive patients, capravirine showed antiretroviral activity when used alone for a short period of time, and achieved target antiretroviral concentrations in plasma as a part of a combination therapy. A new double-blind 48-week study will evaluate capravirine for use in two groups of HIV-infected patients: those who have never been treated with anti-HIV medications and those who have failed previous treatment. Capravirine, which has been generally well tolerated by patients, was developed by Agouron Pharmaceuticals, Inc. (Toronto, Canada).



Related Links:
Agouron Pharmaceuticals